
05 Apr 2022
PANMURE: Faron Pharmaceuticals : Focus on bexmarilimab
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
PANMURE: Faron Pharmaceuticals : Focus on bexmarilimab
Faron Pharmaceuticals Oy (FARN:LON) | 205 0 0.0% | Mkt Cap: 229.5m
- Published:
05 Apr 2022 -
Author:
Dr Mike Mitchell | Dr Julie Simmonds -
Pages:
8 -